{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:25:56Z","timestamp":1787405156444,"version":"build-2736575974"},"reference-count":184,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Cutaneous melanoma is a public health problem. Efforts to reduce its incidence have failed, as it continues to increase. In recent years, many risk factors have been identified. Numerous diagnostic systems exist that greatly assist in early clinical diagnosis. The histopathological aspect illustrates the grim nature of these cancers. Currently, pathogenic pathways and the tumor microclimate are key to the development of therapeutic methods. Revolutionary therapies like targeted therapy and immune checkpoint inhibitors are starting to replace traditional therapeutic methods. Targeted therapy aims at a specific molecule in the pathogenic chain to block it, stopping cell growth and dissemination. The main function of immune checkpoint inhibitors is to boost cellular immunity in order to combat cancer cells. Unfortunately, these therapies have different rates of effectiveness and side effects, and cannot be applied to all patients. These shortcomings are the basis of increased incidence and mortality rates. This study covers all stages of the evolutionary sequence of melanoma. With all these data in front of us, we see the need for new research efforts directed at therapies that will bring greater benefits in terms of patient survival and prognosis, with fewer adverse effects.<\/jats:p>","DOI":"10.3390\/clinpract14010018","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T10:44:24Z","timestamp":1706697864000},"page":"214-241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Narrative Review of Current Knowledge on Cutaneous Melanoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Bogdan Marian","family":"Caraban","sequence":"first","affiliation":[{"name":"Clinical Department of Plastic Surgery, Microsurgery\u2013Reconstructive, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"},{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Aschie","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"Clinical Service of Pathology, Departments of Pathology, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"},{"name":"Academy of Medical Sciences of Romania, 030171 Bucharest, Romania"},{"name":"The Romanian Academy of Scientists, 030167 Bucharest, Romania"},{"name":"Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), \u201cOvidius\u201d University of Constanta, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Deacu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"Clinical Service of Pathology, Departments of Pathology, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgeta Camelia","family":"Cozaru","sequence":"additional","affiliation":[{"name":"Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), \u201cOvidius\u201d University of Constanta, 900591 Constanta, Romania"},{"name":"Clinical Service of Pathology, Departments of Genetics, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela Butcaru","family":"Pundiche","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"Clinical Department of General Surgery, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-3200","authenticated-orcid":false,"given":"Cristian Ionut","family":"Orasanu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"Clinical Service of Pathology, Departments of Pathology, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"},{"name":"Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), \u201cOvidius\u201d University of Constanta, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Ioana","family":"Voda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"},{"name":"Clinical Service of Pathology, Departments of Pathology, \u201cSf. Apostol Andrei\u201d Emergency County Hospital, 900591 Constanta, Romania"},{"name":"Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), \u201cOvidius\u201d University of Constanta, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jso.25604","article-title":"Melanoma","volume":"120","author":"Scoggins","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.suc.2019.09.005","article-title":"Epidemiology and Risk Factors of Melanoma","volume":"100","author":"Carr","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Pract. Concept"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-018-0732-8","article-title":"The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe","volume":"20","author":"Dimitriou","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Grossman, D.C., Curry, S.J., Owens, D.K., Barry, M.J., Caughey, A.B., Davidson, K.W., Doubeni, C.A., Epling, J.W., and Kemper, A.R. (2018). Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 1134\u20131142.","DOI":"10.1001\/jama.2018.1623"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jaad.2016.07.045","article-title":"Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review","volume":"76","author":"Brunssen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-20-4092","article-title":"The State of Melanoma: Emergent Challenges and Opportunities","volume":"27","author":"Atkins","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2019.10.008","article-title":"Advances in Prevention and Surveillance of Cutaneous Malignancies","volume":"133","author":"Trager","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jid.2018.06.187","article-title":"Melanoma Early Detection: Big Data, Bigger Picture","volume":"139","author":"Petrie","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14740\/wjon1349","article-title":"Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management","volume":"12","author":"Naik","year":"2021","journal-title":"World J. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.jid.2021.12.003","article-title":"An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975\u20132017","volume":"142","author":"Kurtansky","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pathol.2022.12.345","article-title":"Diagnostic error, uncertainty, and overdiagnosis in melanoma","volume":"55","author":"Elder","year":"2023","journal-title":"Pathology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2021.06.010","article-title":"Evidence concerning the accusation that melanoma is overdiagnosed","volume":"85","author":"Muzumdar","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","first-page":"1236","article-title":"Overdiagnosis of melanoma\u2014Causes, consequences and solutions","volume":"18","author":"Kutzner","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., and Barsouk, A. (2021). Epidemiology of Melanoma. Med. Sci., 9.","DOI":"10.3390\/medsci9040063"},{"key":"ref_17","unstructured":"(2023, August 25). International Agency for Research on Cancer Cancer Tomorrow\u2014Estimated Number of Deaths from 2020 to 2040 of Melanoma of Skin. Available online: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=16&single_unit=5000&group_cancers=1&multiple_cancers=1&types=1."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","article-title":"New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986\u20132016","volume":"110","author":"Stein","year":"2020","journal-title":"Am. J. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lopes, J., Rodrigues, C.M.P., Gaspar, M.M., and Reis, C.P. (2022). Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14.","DOI":"10.3390\/cancers14194652"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moreira, A., Heinzerling, L., Bhardwaj, N., and Friedlander, P. (2021). Current Melanoma Treatments: Where Do We Stand?. Cancers, 13.","DOI":"10.3390\/cancers13020221"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117093","DOI":"10.1016\/j.lfs.2019.117093","article-title":"Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges","volume":"240","author":"Moreira","year":"2020","journal-title":"Life Sci."},{"key":"ref_23","first-page":"e15087","article-title":"A Review of Epidemiology and Cancer Biology of Malignant Melanoma","volume":"13","author":"Davey","year":"2021","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"adv00136","DOI":"10.2340\/00015555-3491","article-title":"Melanoma Epidemiology and Sun Exposure","volume":"100","author":"Raimondi","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2021161S","DOI":"10.5826\/dpc.11S1a161S","article-title":"Epidemiology and Risk Factors of Melanoma: A Review","volume":"11","author":"Conforti","year":"2021","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CMR.0000000000000609","article-title":"Ultraviolet radiation and cutaneous melanoma: A historical perspective","volume":"30","author":"Autier","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vechtomova, Y.L., Telegina, T.A., Buglak, A.A., and Kritsky, M.S. (2021). UV Radiation in DNA Damage and Repair Involving DNA-Photolyases and Cryptochromes. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111564"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fonc.2020.00951","article-title":"Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jdv.15964","article-title":"The association between pesticide use and cutaneous melanoma: A systematic review and meta-analysis","volume":"34","author":"Stanganelli","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116280","DOI":"10.1016\/j.taap.2022.116280","article-title":"A systematic review of mechanistic studies on the relationship between pesticide exposure and cancer induction","volume":"456","author":"Ataei","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cps.2021.05.001","article-title":"Melanoma Risk Factors and Prevention","volume":"48","author":"Dzwierzynski","year":"2021","journal-title":"Clin. Plast. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cup.13689","article-title":"Germline mutations predisposing to melanoma","volume":"47","author":"Toussi","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103425","DOI":"10.1016\/j.critrevonc.2021.103425","article-title":"Molecular landscape of Hereditary Melanoma","volume":"164","author":"Machado","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000518826","article-title":"Influence of Ethnicities and Skin Color Variations in Different Populations: A Review","volume":"35","author":"Naik","year":"2022","journal-title":"Skin Pharmacol. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/php.12335","article-title":"MC1R, eumelanin and pheomelanin: Their role in determining the susceptibility to skin cancer","volume":"91","author":"Nasti","year":"2015","journal-title":"Photochem. Photobiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/php.13278","article-title":"Oxidative Stress and Genotoxicity in Melanoma Induction: Impact on Repair Rather Than Formation of DNA Damage?","volume":"96","author":"Douki","year":"2020","journal-title":"Photochem. Photobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2023311S","DOI":"10.5826\/dpc.1304S1a311S","article-title":"Race-Specific and Skin of Color Dermatoscopic Characteristics of Skin Cancer: A Literature Review","volume":"13","author":"Karampinis","year":"2023","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/jdv.17242","article-title":"Photoprotection according to skin phototype and dermatoses: Practical recommendations from an expert panel","volume":"35","author":"Passeron","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Yuan, T.A., Lu, Y., Edwards, K., Jakowatz, J., Meyskens, F.L., and Liu-Smith, F. (2019). Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16060908"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40487-020-00109-1","article-title":"Gender Differences and Outcomes in Melanoma Patients","volume":"8","author":"Morgese","year":"2020","journal-title":"Oncol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bellenghi, M., Puglisi, R., Pontecorvi, G., De Feo, A., Car\u00e8, A., and Mattia, G. (2020). Sex and Gender Disparities in Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12071819"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","article-title":"Melanoma in immunosuppressed patients","volume":"87","author":"Kubica","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2018.03.024","article-title":"Risk of skin cancer in patients with HIV: A Danish nationwide cohort study","volume":"79","author":"Omland","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.det.2018.07.009","article-title":"Skin Cancer and Immunosuppression","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1111\/ijd.12564","article-title":"Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia","volume":"54","author":"Brewer","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1038\/onc.2017.189","article-title":"Melanocytic nevi and melanoma: Unraveling a complex relationship","volume":"36","author":"Damsky","year":"2017","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.det.2016.08.001","article-title":"Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence","volume":"35","author":"Huang","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjd.19819","article-title":"A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences","volume":"185","author":"Dessinioti","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shreberk-Hassidim, R., Ostrowski, S.M., and Fisher, D.E. (2023). The Complex Interplay between Nevi and Melanoma: Risk Factors and Precursors. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043541"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ije\/dyaa009","article-title":"Body mass index and height and risk of cutaneous melanoma: Mendelian randomization analyses","volume":"49","author":"Dusingize","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000502129","article-title":"Cigarette Smoking and the Risk of Cutaneous Melanoma: A Case-Control Study","volume":"236","author":"Sondermeijer","year":"2020","journal-title":"Dermatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjd.12856","article-title":"Alcohol drinking and cutaneous melanoma risk: A systematic review and dose-risk meta-analysis","volume":"170","author":"Rota","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00394-018-1613-5","article-title":"Alcohol, alcoholic beverages, and melanoma risk: A systematic literature review and dose-response meta-analysis","volume":"57","author":"Gandini","year":"2018","journal-title":"Eur. J. Nutr."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Smith, L.K., Arabi, S., Lelliott, E.J., McArthur, G.A., and Sheppard, K.E. (2020). Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?. Cancers, 12.","DOI":"10.3390\/cancers12061583"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcancer.2023.02.010","article-title":"Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies","volume":"91","author":"Roccuzzo","year":"2023","journal-title":"Semin Cancer Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/bjd.13998","article-title":"Smoking is inversely related to cutaneous malignant melanoma: Results of a meta-analysis","volume":"173","author":"Li","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_57","first-page":"241","article-title":"Cutaneous melanomas","volume":"13","author":"Rutkowski","year":"2017","journal-title":"Oncol. Clin. Pract."},{"key":"ref_58","first-page":"1005","article-title":"Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"Vivo"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Singh, D., Gautam, D., and Ahmed, M. (2014). Detection Techniques for Melanoma Diagnosis: A Performance Evaluation, ICSPCT.","DOI":"10.1109\/ICSPCT.2014.6884948"},{"key":"ref_60","first-page":"S39","article-title":"Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination","volume":"35","author":"Holmes","year":"2018","journal-title":"Fed. Pract."},{"key":"ref_61","first-page":"1080","article-title":"Dermoscopy for the Diagnosis of Melanoma: An Overview","volume":"4","author":"Togawa","year":"2017","journal-title":"Austin J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.det.2017.06.003","article-title":"Enhancing Skin Cancer Diagnosis with Dermoscopy","volume":"35","author":"Wolner","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2006.09.003","article-title":"The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy","volume":"56","author":"Henning","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2133.2010.10194.x","article-title":"Seven-point checklist of dermoscopy revisited","volume":"164","author":"Argenziano","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/1346-8138.13201","article-title":"CASH algorithm versus 3-point checklist and its modified version in evaluation of melanocytic pigmented skin lesions: The 4-point checklist","volume":"43","author":"Stinco","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","article-title":"Melanoma: Clinical Presentations","volume":"167","author":"Kibbi","year":"2016","journal-title":"Cancer Treat Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Balch, C.M., Atkins, M.B., Gabre, C., Gershenwald, J.E., Halpern, A.C., Kirkwood, J.M., McArthur, G.A., Thompson, J.F., and Sober, A.J. (2020). Cutaneous Melanoma, Springer. [6th ed.].","DOI":"10.1007\/978-3-319-46029-1"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1245\/s10434-021-09866-3","article-title":"Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis","volume":"28","author":"Ahmadi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/ajd.13004","article-title":"Accuracy of partial biopsies in the management of cutaneous melanoma","volume":"60","author":"Doolan","year":"2019","journal-title":"Australas J. Dermatol."},{"key":"ref_70","unstructured":"WHO Classification of Tumours Editorial Board (2023, August 25). Skin Tumours [Internet; Beta Version ahead of Print], Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/64."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: What do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Strashilov, S., and Yordanov, A. (2021). Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126395"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.29245\/2767-5092\/2021\/3.1144","article-title":"Nodular Melanoma: A Review of Pathogenesis, Presentation, Diagnosis, and Treatment","volume":"3","author":"Hernandez","year":"2021","journal-title":"J. Dermatol. Skin Sci."},{"key":"ref_75","first-page":"1","article-title":"Melanoma\u2014Clinical, dermatoscopical, and histopathological morphological characteristics","volume":"22","author":"Situm","year":"2014","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"635488","DOI":"10.3389\/fonc.2021.635488","article-title":"Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies","volume":"11","author":"Scatena","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Massone, C., Hofman-Wellenhof, R., Chiodi, S., and Sola, S. (2021). Dermoscopic Criteria, Histopathological Correlates and Genetic Findings of Thin Melanoma on Non-Volar Skin. Genes, 12.","DOI":"10.3390\/genes12081288"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jclinpath-2020-207051","article-title":"Pitfalls in the diagnosis of lentigo maligna and lentigo maligna melanoma, facts and an opinion","volume":"74","author":"Sina","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CMR.0000000000000619","article-title":"Estimated risk of progression of lentigo maligna to lentigo maligna melanoma","volume":"30","author":"Menzies","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anndiagpath.2016.08.005","article-title":"Histopathological diagnosis of acral lentiginous melanoma in early stages","volume":"26","author":"Cassarino","year":"2017","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaad.2019.01.081","article-title":"Early detection of acral melanoma: A review of clinical, dermoscopic, histopathologic, and molecular characteristics","volume":"81","author":"Darmawan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12967-022-03532-2","article-title":"Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma","volume":"20","author":"Gui","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-021-10089-9","article-title":"Sentinel lymph node biopsy in melanoma: Beyond histologic factors","volume":"39","author":"Carr","year":"2022","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ans.13286","article-title":"Review of the role of sentinel node biopsy in cutaneous head and neck melanoma","volume":"86","author":"Roy","year":"2016","journal-title":"ANZ J. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11864-021-00819-2","article-title":"Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma","volume":"22","author":"Morrison","year":"2021","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1245\/s10434-018-6812-z","article-title":"The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma","volume":"26","author":"Hieken","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Dixon, A.J., Kyrgidis, A., Steinman, H.K., Dixon, J.B., Sladden, M., Garbe, C., Lallas, A., Zachary, C.B., Leiter-St\u00f6ppke, U., and Smith, H. (2024). Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. J. Eur. Acad. Dermatol. Venereol., in press.","DOI":"10.1111\/jdv.19772"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjd.19499","article-title":"Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"184","author":"Mulder","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ijd.15594","article-title":"Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study","volume":"60","author":"Yousaf","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_93","first-page":"1071","article-title":"Cutaneous melanoma: From pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_94","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.20421","article-title":"Melanoma genomics: A state-of-the-art review of practical clinical applications","volume":"185","author":"Guhan","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cncr.30593","article-title":"Somatic driver mutations in melanoma","volume":"123","author":"Reddy","year":"2017","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Nepote, A., Avallone, G., Ribero, S., Cavallo, F., Roccuzzo, G., Mastorino, L., Conforti, C., Paruzzo, L., Poletto, S., and Carnevale Schianca, F. (2022). Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030828"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hoc.2020.08.010","article-title":"Biology of Melanoma","volume":"35","author":"Ostrowski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Car\u00e8, A., and Mattia, G. (2021). Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13122875"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Chamcheu, J.C., Roy, T., Uddin, M.B., Banang-Mbeumi, S., Chamcheu, R.N., Walker, A.L., Liu, Y.Y., and Huang, S. (2019). Role and Therapeutic Targeting of the PI3K\/Akt\/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells, 8.","DOI":"10.3390\/cells8080803"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Manning","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: Role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Karagianni, F., Pavlidis, A., Malakou, L.S., Piperi, C., and Papadavid, E. (2022). Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031693"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"665647","DOI":"10.3389\/fmed.2021.665647","article-title":"Recent Updates on the Involvement of PI3K\/AKT\/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders","volume":"8","author":"Mercurio","year":"2021","journal-title":"Front. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Cabrita, R., Mitra, S., Sanna, A., Ekedahl, H., L\u00f6vgren, K., Olsson, H., Ingvar, C., Isaksson, K., Lauss, M., and Carneiro, A. (2020). The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers, 12.","DOI":"10.3390\/cancers12030742"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/cup.13691","article-title":"TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis","volume":"47","author":"Motaparthi","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6300329","DOI":"10.1155\/2022\/6300329","article-title":"TERT Promoter Mutations and Telomerase in Melanoma","volume":"2022","author":"Guo","year":"2022","journal-title":"J. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","article-title":"KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development","volume":"20","author":"Meng","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and Melanoma: Biological Insights and Clinical Implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_111","first-page":"163","article-title":"Melanoma Development: Current Knowledge on Melanoma Pathogenesis","volume":"27","year":"2019","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Gelmi, M.C., Houtzagers, L.E., Strub, T., Krossa, I., and Jager, M.J. (2022). MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116001"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/pcmr.13053","article-title":"The MITF regulatory network in melanoma","volume":"35","author":"Chauhan","year":"2022","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.trecan.2020.02.021","article-title":"RAC1 as a Therapeutic Target in Malignant Melanoma","volume":"6","author":"Cannon","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Czyz, M. (2018). HGF\/c-MET Signaling in Melanocytes and Melanoma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123844"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"785153","DOI":"10.3389\/fgene.2021.785153","article-title":"Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Tardiel-Cyril, D.R., Davtyan, A., Generali, D., Roudi, R., and Li, Y. (2021). CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers, 13.","DOI":"10.20944\/preprints202102.0150.v1"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"608024","DOI":"10.3389\/fimmu.2020.608024","article-title":"Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types","volume":"11","author":"Konduri","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Caraban, B.M., Matei, E., Cozaru, G.C., A\u015fchie, M., Deacu, M., Enciu, M., B\u0103l\u0163\u0103tescu, G.I., Chisoi, A., Dobrin, N., and Petcu, L. (2023). PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. J. Pers. Med., 13.","DOI":"10.3390\/jpm13020221"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jmir.2019.05.001","article-title":"The Pathogenesis and Clinical Management of Cutaneous Melanoma: An Evidence-Based Review","volume":"50","author":"Burns","year":"2019","journal-title":"J. Med. Imaging Radiat. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.suc.2019.09.001","article-title":"Surgical Management of Primary Cutaneous Melanoma","volume":"100","author":"Joyce","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11912-019-0798-y","article-title":"Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma","volume":"21","author":"Zommorodi","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1158\/1078-0432.CCR-19-1194","article-title":"Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma","volume":"25","author":"Namikawa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14712598.2017.1289169","article-title":"Role of interferon in melanoma: Old hopes and new perspectives","volume":"17","author":"Sanlorenzo","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: An individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-021-01064-4","article-title":"Cytokines in the Treatment of Melanoma","volume":"23","author":"Bentebibel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: A systematic review","volume":"26","author":"Simeone","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Choudhry, H., Helmi, N., Abdulaal, W.H., Zeyadi, M., Zamzami, M.A., Wu, W., Mahmoud, M.M., Warsi, M.K., Rasool, M., and Jamal, M.S. (2018). Prospects of IL-2 in Cancer Immunotherapy. Biomed Res. Int., 2018.","DOI":"10.1155\/2018\/9056173"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2015.11.011","article-title":"Metastatic melanoma treatment: Combining old and new therapies","volume":"98","author":"Davey","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","article-title":"High-dose interleukin-2 (IL-2) for the treatment of melanoma: Safety considerations and future directions","volume":"16","author":"Marabondo","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/mmt-2017-0003","article-title":"The role for chemotherapy in the modern management of melanoma","volume":"4","author":"Gupta","year":"2017","journal-title":"Melanoma Manag."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","article-title":"Chemotherapy for Melanoma","volume":"167","author":"Wilson","year":"2016","journal-title":"Cancer Treat Res."},{"key":"ref_140","first-page":"680","article-title":"Temozolomide for Treating Malignant Melanoma","volume":"25","author":"Li","year":"2015","journal-title":"J. Coll. Physicians Surg Pak."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Li, B., Jin, J., Guo, D., Tao, Z., and Hu, X. (2023). Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers, 15.","DOI":"10.3390\/cancers15102858"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","article-title":"Vemurafenib","volume":"211","author":"Garbe","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Australian Prescriber (2013). Dabrafenib for metastatic melanoma. Aust. Prescr., 37, 28\u201335.","DOI":"10.18773\/austprescr.2014.014"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials","volume":"125","author":"Hauschild","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","article-title":"Development of encorafenib for BRAF-mutated advanced melanoma","volume":"30","author":"Koelblinger","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14656566.2019.1694664","article-title":"An evaluation of encorafenib for the treatment of melanoma","volume":"21","author":"Carr","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17460441.2020.1746265","article-title":"The discovery and development of binimetinib for the treatment of melanoma","volume":"15","author":"Tran","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., and Scalvenzi, M. (2022). The Treatment of Advanced Melanoma: Therapeutic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126388"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1060028016672037","article-title":"Cobimetinib: A Novel MEK Inhibitor for Metastatic Melanoma","volume":"51","author":"Signorelli","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/fon-2018-0659","article-title":"Cobimetinib in malignant melanoma: How to MEK an impact on long-term survival","volume":"15","author":"Indini","year":"2019","journal-title":"Future Oncol."},{"key":"ref_154","first-page":"741","article-title":"Trametinib: A Targeted Therapy in Metastatic Melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","article-title":"MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors","volume":"18","author":"Grimaldi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"74","DOI":"10.18773\/austprescr.2015.028","article-title":"Medical management of malignant melanoma","volume":"38","author":"Atkinson","year":"2015","journal-title":"Aust. Prescr."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: Towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CCO.0000000000000606","article-title":"Targeted therapies in melanoma beyond BRAF: Targeting NRAS-mutated and KIT-mutated melanoma","volume":"32","author":"Delyon","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted Therapy and Immunotherapy for Melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., and Milella, M. (2020). Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12102870"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: A Review in Advanced Melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., and Cocorocchio, E. (2021). Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14010081"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Boydell, E., Sandoval, J.L., Michielin, O., Obeid, M., Addeo, A., and Friedlaender, A. (2023). Neoadjuvant Immunotherapy: A Promising New Standard of Care. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411849"},{"key":"ref_169","unstructured":"National Library of Medicine (2023, December 07). ClinicalTrials.gov. Search Results: Cutaneous Melanoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/results?pg=1&load=cart&id=NCT04091750+OR+NCT03149029+OR+NCT04068181+OR+NCT02967692+OR+NCT00539591+OR+NCT02908672+OR+NCT02362594+OR+NCT00003641+OR+NCT01844505+OR+NCT02581930+OR+NCT03698019+OR+NCT01708941+OR+NCT01134614+OR+NCT00937937+OR+NCT04099251+OR+NCT03553836+OR+NCT03470922+OR+NCT02388906+OR+NCT01274338+OR+NCT02743819."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M.A., Zalaudek, I., and Puglisi, F. (2021). Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13081819"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: The tumor MHC dilemma","volume":"66","author":"Garrido","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological Consequences of MHC-II Expression by Tumor Cells in Cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/immuno2040041","article-title":"Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade","volume":"2","author":"Moise","year":"2022","journal-title":"Immuno"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"654749","DOI":"10.3389\/fimmu.2021.654749","article-title":"Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing Metastatic Melanoma in 2022: A Clinical Review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"Immunotargets Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Huang, L., Guo, Y., Liu, S., Wang, H., Zhu, J., Ou, L., and Xu, X. (2021). Targeting regulatory T cells for immunotherapy in melanoma. Mol. Biomed., 2.","DOI":"10.1186\/s43556-021-00038-z"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Comito, F., Pagani, R., Grilli, G., Sperandi, F., Ardizzoni, A., and Melotti, B. (2022). Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14020271"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/1\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:44Z","timestamp":1760104184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":184,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["clinpract14010018"],"URL":"https:\/\/doi.org\/10.3390\/clinpract14010018","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}